A deal with AbbVie and new preclinical data demonstrating the potential of its masked T-cell engagers have helped revive the fortunes of struggling small-cap biotech Xilio Therapeutics.
The big pharma company will pay $52m upfront to the biotech to develop novel tumor-activated immunotherapies, including masked T-cell engagers (TCEs) with Xilio eligible for a
Key Takeaways
- 'Masking' technology aims to target TCEs to tumor cells and spare healthy tissue, and Janux's JANX007's has set the pace in the field
